Revolutionizing Mitochondrial Disease Prevention: The Three-Parent Baby Technology

📅 Publication Details and Scientific Context

This article is based on data from three separate scientific documents simultaneously published in The New England Journal of Medicine (NEJM) on July 16, 2025:

• Original Research: Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease
• Brief Clinical Report: Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease
• Editorial Review: Advances in Preventing Transmission of Mitochondrial DNA Diseases

---

💉 Mitochondrial Diseases: Definitions, Examples, and Prevalence

Mitochondrial diseases are inherited metabolic disorders that impair the mitochondria’s ability to produce energy. They typically result from mutations in the mitochondrial DNA (mtDNA) passed down from the mother.

Most Well-Known Mitochondrial Diseases:

• Leigh Syndrome
• MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes)
• LHON (Leber’s Hereditary Optic Neuropathy)
• MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

Prevalence:

• Approximately 1 in 4,300 individuals is affected by a mitochondrial disease.
• 1 in every 200 people may carry a pathogenic mtDNA variant.

Common Symptoms:

• Muscle weakness and exercise intolerance
• Cardiomyopathy
• Vision and hearing loss
• Seizures
• Developmental delays
• Encephalopathy and stroke-like episodes

The severity of symptoms is associated with the level of heteroplasmy.

---

🧬 What is Mitochondrial Donation?

Mitochondrial donation involves transferring the nucleus from a fertilized egg of a woman with diseased mitochondria into a donor egg that has had its own nucleus removed.

• It is suitable for homoplasmic women (those with 100% affected mtDNA).
• It is also preferred in cases with a high level of heteroplasmy.

⚖️ Scope and Design of the Scientific Study

This comparative observational study aimed to evaluate the real-world outcomes of two assisted reproductive technologies in women who carry mitochondrial disease.

A total of 61 women carrying pathogenic mitochondrial DNA (mtDNA) variants were enrolled. Based on their mutation load (heteroplasmy level) and personal preferences, they were divided into two groups:

• 22 women received Pronuclear Transfer mitochondrial donation.

• 39 women underwent Preimplantation Genetic Testing (PGT).

---

What is PGT?

Preimplantation Genetic Testing (PGT) involves removing a few cells from embryos created via conventional IVF and performing genetic analysis. In women carrying mtDNA mutations, the mutant mitochondrial load (heteroplasmy) of each embryo is measured. Only low-risk embryos are transferred to prevent disease transmission.

This research revealed the strengths of pronuclear transfer and PGT in terms of both efficacy and safety, offering practical clinical guidance on which strategy may be more suitable for different patient groups.

Figure 1. Pronuclear-Transfer Procedure and Comparison of Embryo Development with Pronuclear Transfer and with PGT.

Panel A shows the pronuclear-transfer procedure. The images in Panel B show the enucleation of patient karyoplasts and the fusion of patient karyoplasts with the donor egg cytoplast (scale bar, 20 μm). Arrows in the first image indicate the pronuclei, and arrows in the fourth image indicate the karyoplasts. Panel C shows a comparison of the percentage of embryos with blastocyst formation on days 5 and 6 after intracytoplasmic sperm injection in the pronuclear-transfer group and in the PGT group. The images in panel D show examples of top-quality and good-quality pronuclear-transfer blastocysts (scale bar, 20 μm). Panel E shows the percentage of blastocysts that were top quality or good quality after pronuclear transfer and after PGT on days 5 and 6. The percentage was higher in the pronuclear-transfer group than the PGT group on both day 5 (P=0.04 by chi-square test) and day 6 (P=0.006 by chi-square test).

---

📊 Study Data

Method	Pregnancy Rate	Live Births
Pronuclear Transfer	36% (8/22)	8 + 1 ongoing
PGT	41% (16/39)	18

🧬 mtDNA (Heteroplasmy) Levels in Newborns

Genetic analysis of blood samples from newborns revealed the proportion of pathogenic variants in mitochondrial DNA (% heteroplasmy). This level is a critical marker of the child's disease risk.

• In babies born via Pronuclear Transfer:
  • Heteroplasmy levels ranged from 0% to 16%.
  • In 6 babies, the level of mutated mtDNA was reduced by 95% to 100%.
  • In 2 babies, the reduction was between 77% and 88%.
• In babies born via PGT: Heteroplasmy levels ranged from 0% to 7%.

Note: Medically, heteroplasmy levels below 15% are generally considered non-pathogenic and safe.

---

👶 Clinical Follow-up and Health Outcomes

Newborns were regularly monitored for health status after birth. The findings are as follows:

• All babies were assessed as healthy at birth.
• Only 2 babies showed mild and temporary side effects:
  • One baby had infantile myoclonic epilepsy (resolved spontaneously without requiring treatment).
  • The other had a congenital heart rhythm disorder (associated with hyperlipidemia); it responded completely to medical therapy.

📌 Conclusion